Studies related to TNF-Alpha and Trimethylglycine

Betaine For Nonalcoholic Fatty Liver Disease: Results Of A Randomized Placebo-controlled Trial

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 34
Sex Both Genders
Age Range 30-44, 45-64, 65+
Body Types Obese
Notes for this study:
Supplementation of 10g betaine twice daily for one year in persons with nonalcoholic fatty liver disease was able to increase methionine and SAMe levels, but did not reduce S-adenosylhomocysteine levels. Alongside this, there were failures to reduce liver enzymes or fibrotic scores, although liver fat (steatosis) was reduced with betaine and the progression of the disease state was lower in betaine relative to placebo.

General symptoms and well being was not different between groups.